Skip to main content
. 2020 Mar 4;15(3):e0229621. doi: 10.1371/journal.pone.0229621

Fig 4. Time trends in patient proportions with acute myocardial infarction (AMI), heart failure (HF), or stroke at baseline.

Fig 4

AMI: acute myocardial infarction; HF: heart failure; DPP-4i: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonists; SGLT2i: sodium-glucose cotransporter 2 inhibitors; TECOS: Sitagliptin (DPP-4i) showed non-inferiority to placebo [35]; Lira obesity label: Liraglutide 3 mg launched as treatment for obesity; EMPA-REG OUTCOME: empagliflozin showed CV and CV/all-cause mortality benefits [10], LEADER: liraglutide showed CV and CV/all-cause mortality benefits [12]; CANVAS: canagliflozin showed CV benefits [11].